May typically sees weaker stock performance, but it can also present strategic buying opportunities for long-term investors. This month, three stocks stand out as potential buys: TransMedics Group, Rhythm Pharmaceuticals, and Enbridge. TransMedics (NASDAQ: TMDX) has faced a significant decline following a Q1 earnings miss, despite a 21% revenue increase. Its innovative organ transplant technology and expansion plans in Europe could position it for future growth, particularly with the development of a kidney transplant system.

Rhythm Pharmaceuticals (NASDAQ: RYTM) has also experienced a downturn but is rebounding after receiving regulatory approvals for its obesity drug, Imcivree. With a growing patient population and upcoming trial results, the company is poised for momentum.

For risk-averse investors, Enbridge (NYSE: ENB) offers stability, transporting a significant portion of North America’s crude oil and natural gas. With a solid dividend yield of 5.2% and a robust growth pipeline, Enbridge represents a reliable investment amid market volatility.

Source: fool.com